{"disease":{"id":"nimotuzumab","name":"nimotuzumab"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04136600","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT06429839","title":"Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04207918","title":"A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06410651","title":"Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04664244","title":"Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03554889","title":"Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":21,"lead_sponsor_name":"Hangzhou Cancer Hospital","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}